Amifer syrup

Form: Syrup
Dosage: 30 mg/5ml
Packaging: Bottle 200 ml

Active substance:  Elemental iron – Folic acid (Vit B9) – Cyanocobalamin Vit B12

Form: Solution – Syrup

Dosage: per 5 ml

  • Elemental iron 30 mg/5ml
  • Folic acid (Vit B9) 2.5 mg/5ml
  • Cyanocobalamin (Vit B 12) 0.02mg/5ml

Packaging: Box with 200ml syrup and a plastic graduated measuring cup.

Target : adults and children (as from 1 y)  – For infants Amifer® Junior Syrup is available in several countries

  • Prophylaxis and treatment of iron and folic acid deficiencies during pregnancy and the following weeks as well as during breastfeeding. Specific prophylaxis is also recommended during the second and third trimesters of pregnancy.
  • Treatment of iron deficiency anaemia. It is essential to make an accurate diagnosis before starting treatment.
  • Treatment preventing iron and folic acid deficiencies in case of low dietary iron and folic acid supplementation.
  • Prevention of neural tube defects with folic acid is recommended before conception and during the first trimester of pregnancy

IRON SUPPLEMENTS  (= to reduce deficiencies and replenish reserves)

Folic acid and Vit B12 supplementation

  • Age: 1-13y
    • Quantity in ml: 5 ml
  • Age: Adolescents and adults
    • Quantity in ml: 10 ml
  • pregnancy and breast feeding
    • Quantity in ml: 10 ml

In case of anemia double the doses

Over-the-counter drug

Notice of Trademark Infringement

Dear valued partners, customers and Dafra representatives,

It has come to our attention that unauthorized use of our company’s name and logo has been observed in various contexts in the African country Togo ( In order to avoid misunderstandings, ever misleading, we feel it is imperative to address this issue promptly and transparently.

Trademark infringement poses a significant threat not only to our brand integrity but also to the trust and credibility we have worked diligently to establish within our community. Our name and logo represent our values, quality, and commitment to excellence, and any unauthorized use undermines these principles.

We take trademark infringement seriously and are actively taking measures to address any instances of unauthorized use. This includes legal action against parties found to be infringing upon our intellectual property rights.

We urge our customers, partners, African representatives and the general public to remain vigilant and report any suspected instances of trademark infringement directly to us. Your cooperation in this matter is crucial in helping us protect our brand and preserve the integrity of our business.

As always, we remain dedicated to providing high quality medical solutions in the sub-Sahara region of Africa and maintaining the highest standards of integrity and professionalism.

Thank you for your continued support and trust in our company.

Dafra Pharma